Skip to main content

Table 2 Univariate analysis of enrolled patients

From: Effect of the duration of the capecitabine regimen following colon cancer surgery in an elderly population: a retrospective cohort study

Variables Mean ± SD/N (%) Disease-free survival Cancer-specific survival
HR (95% CI), P value HR (95% CI), P value
Postoperative capecitabine duration 4.65 ± 6.75 0.91 (0.86, 0.98), 0.014 0.90 (0.84, 0.97), 0.0043
  0 143 (55.64%) 1.0 1.0
   ≤ 12 weeks 79 (30.74%) 0.52 (0.36, 0.98), 0.030 0.48 (0.24, 0.99), 0.046
   ≤ 24 weeks 35 (13.62%) 0.26 (0.19, 0.70), 0.007 0.09 (0.01, 0.67), 0.018
Gender
  Male 161 (62.65%) 1.0 1.0
  Female 96 (37.35%) 1.07 (0.58–1.68), 0.21 1.12 (0.60, 2.08), 0.73
Age (years) 75.83 ± 4.60 1.04 (0.73–1.44), 0.77 1.06 (0.99, 1.12), 0.080
   ≥ 70, < 75 114 (44.36%) 1.0 1.0
   ≥ 75, < 80 84 (32.68%) 1.23 (0.73–2.88), 0.079 1.57 (0.77, 3.19), 0.21
   ≥ 80 59 (22.96%) 1.42 (0.75–3.13), 0.23 1.79 (0.83, 3.87), 0.14
T stage
  1–2 11 (4.28%) 1.0 1.0
  3 211 (82.10%) 1.40 (0.65–5.35), 0.42 1.30 (0.31, 5.44), 0.71
  4 35 (13.62%) 1.22 (0.92–5.57), 0.069 1.13 (0.23, 5.62), 0.88
N stage
  0 128 (49.81%) 1.0 1.0
  1 104 (40.47%) 1.10 (0.67–3.64), 0.45 1.77 (0.85, 3.67), 0.13
  2 25 (9.73%) 4.04 (1.93–8.99), < 0.0001 5.31 (2.42, 11.64), < 0.0001
Stage
  II 128 (49.81%) 1.0 1.0
  III 129 (50.19%) 2.19 (1.13, 4.66), 0.017 2.45 (1.26, 4.78), 0.0083
Histological type
  Common type 221 (85.99%) 1.0 1.0
  Special type 36 (14.01%) 1.28 (0.75–2.96), 0.061 1.69 (0.83, 3.44), 0.15
CEA
  Normal 163 (63.42%) 1.0 1.0
  Elevated 94 (36.58%) 1.29 (0.88–2.42), 0.38 1.15 (0.62, 2.12), 0.66
CA199
  Normal 209 (81.64%) 1.0 1.0
  Elevated 47 (18.36%) 2.68 (1.98–3.93), 0.0075 2.04 (1.04, 3.98), 0.037
Charlson comorbidity index
   ≤ 4 197 (76.65%) 1.0 1.0
   > 4 60 (23.35%) 1.18 (0.61–3.09), 0.87 1.05 (0.50, 2.19), 0.90
MMR status
  dMMR 20 (7.78%) 1.0 1.0
  pMMR 185 (71.98%) 0.79 (0.42, 1.93), 0.57 0.51 (0.21, 1.23), 0.1338
  Unknown 52 (20.23%) 0.67 (0.29, 1.84), 0.12 0.63 (0.22, 1.76), 0.3769
  1. Abbreviations: HR hazard ratio; CI confidence interval; CA carcinoma antigen; CEA carcinoembryonic antigen; MMR mismatch repair; dMMR mismatch repair deficiency; pMMR proficient mismatch repair